Reneo Pharmaceuticals Inc - Class A

Research Reneo Pharmaceuticals Inc - Class A (OKUR) on Bullrun: market cap USD 181.78M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerOKUR
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 181.78M
• Financial periodFY2025
• Net income-USD 59.52M
• Free cash flow-USD 51.87M

Valuation Snapshot

latest market cap is USD 181.78M.

About Reneo Pharmaceuticals Inc - Class A

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.

Frequently asked questions

What is Reneo Pharmaceuticals Inc - Class A's market cap?

Reneo Pharmaceuticals Inc - Class A's market capitalization is USD 181.78M.

What does Reneo Pharmaceuticals Inc - Class A do?

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases.